Abstract:Rapid evolution of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and influenza A virus (IAV) poses enormous challenge in the development of broad-spectrum antivirals that are effective against the existing and emerging viral strains. Virus entry through endocytosis represents an attractive target for drug development, as inhibition of this early infection step should block downstream infection processes, and potentially inhibit viruses sharing the same entry route. In this study, we report the identification of 1,3-diphenylurea (DPU) derivatives (DPUDs) as a new class of endocytosis inhibitors, which broadly restricted entry and replication of several SARS-CoV-2 and IAV strains. Importantly, the DPUDs did not induce any significant cytotoxicity at concentrations effective against the viral infections. Examining the uptake of cargoes specific to different endocytic pathways, we found that DPUDs majorly affected clathrin-mediated endocytosis, which both SARS-CoV-2 and IAV utilize for cellular entry. In the DPUD-treated cells, although virus binding on the cell surface was unaffected, internalization of both the viruses was drastically reduced. Since compounds similar to the DPUDs were previously reported to transport anions including chloride (Cl - ) across lipid membrane and since intracellular Cl - concentration plays a critical role in regulating vesicular trafficking, we hypothesized that the observed defect in endocytosis by the DPUDs could be due to altered Cl - gradient across the cell membrane. Using in vitro assays we demonstrated that the DPUDs transported Cl - into the cell and led to intracellular Cl - accumulation, which possibly affected the endocytic machinery by perturbing intracellular Cl - homeostasis. Finally, we tested the DPUDs in mice challenged with IAV and mouse-adapted SARS-CoV-2 (MA 10). Treatment of the infected mice with the DPUDs led to remarkable body weight recovery, improved survival and significantly reduced lung viral load, highlighting their potential for development as broad-spectrum antivirals. Many pathogenic viruses including SARS-CoV-2 and IAV exploit endocytic pathways to initiate internalization into the host cell, and therefore, inhibiting these pathways with small molecules should effectively restrict viruses at the initial phase of infection. However, cytotoxicity represents one of the major obstacles in the therapeutic use of endocytosis inhibitors, as disruption of endocytosis may severely impact cell health. In this study, we identified DPUDs as a novel class of endocytosis inhibitors, which robustly blocked several IAV strains and SARS-CoV-2 variants of concern (VOC) in tissue culture cells. Remarkably, the DPUDs did not display any significant cytotoxicity at concentrations effective against the viruses. Our data indicate, among different endocytic pathways, clathrin-mediated endocytosis was most sensitive to DPUD treatment. We found that the DPUDs transported chloride ions into the cell, and disrupted endocytic trafficking possibly by perturbing intracellular chloride homeostasis. Confirming the antiviral activity of DPUDs in tissue culture cells, we evaluated their therapeutic potential in animal models of SARS-CoV-2 and influenza infections. SARS-CoV-2- or IAV-infected mice that received DPUD treatment displayed remarkable improvement in survival and clinical features as compared to the control animals, indicating their potential to be developed as highly-effective, broad-spectrum antivirals.

Aglycone polyether ionophores as broad-spectrum agents inhibit multiple enveloped viruses including SARS-CoV-2 in vitro and successfully cure JEV infected mice

In vitro and in vivo effects of 3-indoleacetonitrile-A potential new broad-spectrum therapeutic agent for SARS-CoV-2 infection

The Analogs of Furanyl Methylidene Rhodanine Exhibit Broad-Spectrum Inhibitory and Inactivating Activities against Enveloped Viruses, including SARS-CoV-2 and Its Variants

Broad-spectrum virucidal activity of bacterial secreted lipases against flaviviruses, SARS-CoV-2 and other enveloped viruses

Two novel compounds inhibit Flavivirus infection in vitro and in vivo by targeting lipid metabolism

Rational Development of Hypervalent Glycan Shield-Binding Nanoparticles with Broad-Spectrum Inhibition against Fatal Viruses Including SARS-CoV-2 Variants

Cross-linking Peptide and Repurposed Drugs Inhibit Both Entry Pathways of SARS-CoV-2

Identification of diphenylurea derivatives as novel endocytosis inhibitors that demonstrate broad-spectrum activity against SARS-CoV-2 and influenza A virus both in vitro and in vivo

Extracellular disintegration of viral proteins as an innovative strategy for developing broad-spectrum antivirals against coronavirus

Synthesis of naphthoquinone-fused enediyne sugar polysulfates for nanomolar inhibition of coronavirus

Design, Synthesis, and Biological Evaluation of Peptidomimetic Aldehydes as Broad-Spectrum Inhibitors against Enterovirus and SARS-CoV-2

Novel antiviral discoveries for Japanese encephalitis virus infections through reporter virus‐based high‐throughput screening

Synthesis and antiviral property of polysulfate-grafted maleimide-based enediynes

Antiviral Effect of Antimicrobial Peptoid TM9 and Murine Model of Respiratory Coronavirus Infection

Inhibition of influenza A virus and SARS-CoV-2 infection or co-infection by griffithsin and griffithsin-based bivalent entry inhibitor

Direct inhibitory effect on viral entry of influenza A and SARS‐CoV‐2 viruses by azithromycin

Broad-spectrum antiviral inhibitors targeting pandemic potential RNA viruses

A small molecule compound targeting hemagglutinin inhibits influenza A virus and exhibits broad-spectrum antiviral activity

Structural basis for neutralization of Japanese encephalitis virus by two potent therapeutic antibodies

JIB-04 Has Broad-Spectrum Antiviral Activity and Inhibits SARS-CoV-2 Replication and Coronavirus Pathogenesis

Broad-Spectrum Coronavirus Inhibitors Discovered by Modeling Viral Fusion Dynamics